Mirum Pharmaceuticals, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Christopher Peetz
- Full Time Employees
- 433
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 989 East Hillsdale Boulevard Foster City CA United States of America 94404
- IPO Date
- Jul 18, 2019
- CIK
- 0001759425
- Website
- mirumpharma.com
- Similar Companies
- Business
- Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments for severe rare and orphan diseases, particularly those affecting the liver. The company’s flagship product, LIVMARLI (maralixibat), an ileal bile acid transporter (IBAT) inhibitor, is approved in the United States and Europe for treating cholestatic pruritus in patients with Alagille syndrome (ALGS) aged three months and older (two months and older in Europe). LIVMARLI also holds U.S. approval for cholestatic pruritus in progressive familial intrahepatic cholestasis (PFIC) patients 12 months and older, and European approval for PFIC patients three months and older. Beyond LIVMARLI, Mirum is advancing Volixibat, another IBAT inhibitor, through late-stage clinical studies for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), having reported positive interim results for PBC showing significant improvements in pruritus and fatigue. The company's pipeline further includes CHOLBAM (cholic acid) capsules for bile acid synthesis disorders and CHENODAL (chenodiol) tablets for cerebrotendinous xanthomatosis (CTX), both FDA-approved. Mirum also has MRM-3379, a PDE4D inhibitor, in Phase 2 development for Fragile X syndrome. Mirum Pharmaceuticals, established in 2018 and headquartered in Foster City, California, generates revenue primarily from product sales across key markets including the United States and Europe. The company reported strong financial performance in 2024 and Q3 2025, with increasing product sales and a move to net profitability, leading to raised revenue guidance for 2025.
Company News
Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report?
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
BlackRock Inc. Takes $513.95 Million Position in Mirum Pharmaceuticals, Inc. $MIRM
Deutsche Bank AG Purchases New Holdings in Mirum Pharmaceuticals, Inc. $MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript
Mirum Pharmaceuticals Q2 Earnings Call Highlights
Compared to Estimates, Mirum Pharmaceuticals (MIRM) Q2 Earnings: A Look at Key Metrics
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Beats Revenue Estimates
Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its Portfolio
Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?
Biotech ETF Index Surges 10% After Rebalance
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva